---
title: "特朗普威胁英国国家医疗服务体系面临更高的药品价格"
description: "唐纳德·特朗普正在施压包括葛兰素史克和阿斯利康在内的主要制药公司，要求它们降低美国的药品价格。他建议这些公司应通过提高国外的价格来弥补美国价格的降低，这对英国国家医疗服务体系（NHS）构成潜在威胁"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/251061482.md"
published_at: "2025-07-31T20:33:26.000Z"
---

# 特朗普威胁英国国家医疗服务体系面临更高的药品价格

> 唐纳德·特朗普正在施压包括葛兰素史克和阿斯利康在内的主要制药公司，要求它们降低美国的药品价格。他建议这些公司应通过提高国外的价格来弥补美国价格的降低，这对英国国家医疗服务体系（NHS）构成潜在威胁

Donald Trump is pressuring the world’s biggest drug makers to raise prices outside of the US in a threat to the NHS. The US president has written to pharmaceutical companies including Britain’s GSK and AstraZeneca to demand they lower prices for Americans, suggesting they should pay for it by charging higher fees abroad. It raises the threat of hig...

### Related Stocks

- [GSK.UK - 葛兰素史克](https://longbridge.com/zh-CN/quote/GSK.UK.md)
- [GSK.US - 葛兰素史克](https://longbridge.com/zh-CN/quote/GSK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| GSK Recieves Approval For Exdensur From The European Commission | GSK plc :GSK PLC - EXDENSUR APPROVED BY THE EUROPEAN COMMISSIONGSK PLC - EXDENSUR APPROVED BY THE EUROPEAN COMMISSION | [Link](https://longbridge.com/zh-CN/news/276102835.md) |
| GSK Begins Up to GBP450 Million Share Buyback Tranche | GSK Begins Up to GBP450 Million Share Buyback Tranche | [Link](https://longbridge.com/zh-CN/news/276103252.md) |
| Exdensur approved in EU for severe asthma and CRSwNP | GSK has received European Commission approval for Exdensur (depemokimab), the first ultra-long-acting biologic for sever | [Link](https://longbridge.com/zh-CN/news/276226507.md) |
| Berenberg Bank Keeps Their Hold Rating on GlaxoSmithKline (GSK) | Berenberg Bank analyst Kerry Holford has maintained a Hold rating on GlaxoSmithKline (GSK) with a price target of £20.00 | [Link](https://longbridge.com/zh-CN/news/276103203.md) |
| GSK Begins Fourth Tranche Of Up To GBP 0.45 Bln Share Buyback Under GBP 2 Bln Programme | British drug major GSK plc has announced the commencement of the fourth tranche of its £2 billion share buyback program, | [Link](https://longbridge.com/zh-CN/news/276103384.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。